Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Singh–Franco D et al. – In the studies reviewed, LCZ 5 mg/d was effective in reducing symptoms of PAR, SAR, and CIU and improving QoL, with an acceptable tolerabili–ty profile. There is a need for studies of longer durations, head–to–head comparisons against other anti–histamines, drug–interaction studies, safety studies in infants, and cost–effectiveness analyses.

Related Articles

Allergy drug tackles nasal congestion
Reuters, 11/13/09    Relevance Score: 81%

Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis
Clinical and Experimental Immunology, 10/05/09    Relevance Score: 81%

Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis
Journal of Asthma, 11/11/09    Relevance Score: 79%

Effect of natural seasonal pollen exposure and repeated nasal allergen provocations on elevation of exhaled nitric oxide
Allergy, 10/20/09    Relevance Score: 78%

Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis
Allergy and Asthma Proceedings, 10/13/09    Relevance Score: 78%

Today in Allergy/Immunology...keeping you current

Anti-TNF-[alpha] therapy with infliximab in spondyloarthritides
Expert Review of Clinical Immunology, 12/17/09

Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses
Immunology & Cell Biology, 12/17/09

Allergen IgE-isotype-specific suppression by maternally derived monoclonal anti-IgG-idiotype
Allergy, 12/17/09

Today in Clinical Pharmacology...keeping you current

Resorption and elimination kinetics of benzoic acid during chemical necrectomy in deep burns
Scandinavian Journal of Clinical and Laboratory Investigation, 12/19/09

Dienogest: a new therapeutic agent for the treatment of endometriosis *TEST*
Women's Health, 12/17/09

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address